BIOMAT Database Logo BIOMAT Database Logo

Glutathione infusion potentiates glucose-induced insulin secretion in aged patients with impaired glucose tolerance. 1992

G Paolisso, and D Giugliano, and G Pizza, and A Gambardella, and P Tesauro, and M Varricchio, and F D'Onofrio
Institute of Geriatric Medicine, First Medical School; University of Naples, Italy.

OBJECTIVE To evaluate the effect of glutathione infusion on beta-cell response to glucose in elderly people with impaired glucose tolerance (IGT). METHODS Ten patients with normal glucose tolerance and 10 patients with IGT were matched for age (mean +/- SE, 72.1 +/- 2.8 vs. 71.0 +/- 3.4 yr), body mass index (23.1 +/- 1.1 vs. 22 +/- 2.1 kg/m2), and sex (6/4 vs. 5/5, men/women) underwent glutathione infusion (10 mg/min) under basal conditions and during 75-g oral glucose tolerance tests and intravenous glucose tolerance tests (0.33 g.kg body wt-1.3 min-1). Patients with IGT were also submitted to euglycemic-hyperinsulemic and hyperglycemic glucose clamps. RESULTS In subjects with normal glucose tolerance, glutathione infusion failed to affect beta-cell response to glucose. In contrast, glutathione significantly potentiated glucose-induced insulin secretion in patients with IGT. Furthermore, in the latter group studied by hyperglycemic clamps, glutathione infusion significantly potentiated the beta-cell response to glucose when plasma glucose levels varied between 10 and 15 mM. This effect disappeared at plasma glucose levels greater than 15 mM. No effect of glutathione on insulin clearance and action was observed. CONCLUSIONS Glutathione infusion enhances insulin secretion in elderly people with IGT.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D005978 Glutathione A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides. Reduced Glutathione,gamma-L-Glu-L-Cys-Gly,gamma-L-Glutamyl-L-Cysteinylglycine,Glutathione, Reduced,gamma L Glu L Cys Gly,gamma L Glutamyl L Cysteinylglycine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006943 Hyperglycemia Abnormally high BLOOD GLUCOSE level. Postprandial Hyperglycemia,Hyperglycemia, Postprandial,Hyperglycemias,Hyperglycemias, Postprandial,Postprandial Hyperglycemias
D000078790 Insulin Secretion Production and release of insulin from PANCREATIC BETA CELLS that primarily occurs in response to elevated BLOOD GLUCOSE levels. Secretion, Insulin
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

G Paolisso, and D Giugliano, and G Pizza, and A Gambardella, and P Tesauro, and M Varricchio, and F D'Onofrio
Insulin secretion in Indian patients with impaired glucose tolerance.
November 1986, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
G Paolisso, and D Giugliano, and G Pizza, and A Gambardella, and P Tesauro, and M Varricchio, and F D'Onofrio
Insulin secretion and impaired glucose tolerance.
October 2010, Diabetologia,
G Paolisso, and D Giugliano, and G Pizza, and A Gambardella, and P Tesauro, and M Varricchio, and F D'Onofrio
Increased insulin secretion in subjects with impaired glucose tolerance.
October 1989, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
G Paolisso, and D Giugliano, and G Pizza, and A Gambardella, and P Tesauro, and M Varricchio, and F D'Onofrio
Insulin secretion and insulin sensitivity in people with impaired glucose tolerance.
September 1996, Diabetic medicine : a journal of the British Diabetic Association,
G Paolisso, and D Giugliano, and G Pizza, and A Gambardella, and P Tesauro, and M Varricchio, and F D'Onofrio
Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance.
January 2007, Diabetes research and clinical practice,
G Paolisso, and D Giugliano, and G Pizza, and A Gambardella, and P Tesauro, and M Varricchio, and F D'Onofrio
[Pathogenetic relationship between insulin resistance, insulin secretion and impaired glucose tolerance in patients with obesity].
January 1988, Problemy endokrinologii,
G Paolisso, and D Giugliano, and G Pizza, and A Gambardella, and P Tesauro, and M Varricchio, and F D'Onofrio
Brazilian individuals with impaired glucose tolerance are characterized by impaired insulin secretion.
December 2002, Diabetes & metabolism,
G Paolisso, and D Giugliano, and G Pizza, and A Gambardella, and P Tesauro, and M Varricchio, and F D'Onofrio
Sex-differences in insulin sensitivity and insulin secretion in subjects with impaired fasting glucose and impaired glucose tolerance.
December 2022, Diabetes research and clinical practice,
G Paolisso, and D Giugliano, and G Pizza, and A Gambardella, and P Tesauro, and M Varricchio, and F D'Onofrio
Glucose-induced insulin secretion in dyslipidemic and normolipidemic patients with normal glucose tolerance.
May 2005, Diabetes care,
G Paolisso, and D Giugliano, and G Pizza, and A Gambardella, and P Tesauro, and M Varricchio, and F D'Onofrio
Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance.
May 2000, Diabetes care,
Copied contents to your clipboard!